Volume 22, Number 6—June 2016
Letter
Interferon-γ Autoantibodies as Predisposing Factor for Nontuberculous Mycobacterial Infection
Table
Characteristics | Value |
---|---|
Demographics | |
Female sex | 40 (62.5) |
Median age, y (IQR) | 48.0 (44.8–60.0) |
Asian origin |
59 (92.2) |
Other autoimmune diseases |
7/27 (25.9) |
Etiologic agents | |
Mycobaterium avium | 23 (40.4) |
M. abscessus | 18 (31.6) |
M. fortuitum | 7 (12.3) |
M. tuberculosis |
6 (10.5) |
Other opportunistic infections | 39/52 (75.0) |
Herpesviridae reactivations | 23/52 (44.2) |
Salmonella spp. |
13/52 (25.0) |
Median duration of intensive-phase therapy, mo (IQR) | 31.0 (22.8–60.0) |
≥6 | 31/31 (100) |
≥12 | 29/31 (93.5) |
≥18 | 27/31 (87.1) |
≥24 |
23/31 (74.2) |
Long-term antimicrobial suppressive therapy |
3/30 (10.0) |
Immunomodulatory therapies | 10/30 (33.3) |
Rituximab | 6/30 (20.0) |
IFN-γ | 5/30 (16.7) |
Intravenous immunoglobulins | 2/30 (6.7) |
Plasmapheresis | 2/30 (6.7) |
Cyclophosphamid |
1/30 (3.3) |
Outcome | |
Cure | 21/62 (33.9) |
Improvement | 6/62 (9.7) |
Relapse/persistence | 29/62 (46.8) |
Death |
6/62 (9.7) |
*Values are no. (%) except as indicated. Only articles with sufficient detail were analyzed. A complete listing of articles reviewed from the literature is provided in the online Technical Appendix Table (http://wwwnc.cdc.gov/EID/article/22/6/15-1860-Techapp1.pdf). IQR, interquartile range; IFN-γ, interferon gamma. †Denominators indicate number of case-patients for which category of data was available. |
Page created: May 17, 2016
Page updated: May 17, 2016
Page reviewed: May 17, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.